Eczema sufferers get new hope: pill shows promise after biologic failure

NCT ID NCT07550452

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether switching to a pill called ivarmacitinib can help people with moderate-to-severe eczema (atopic dermatitis) who did not get enough relief from standard injectable drugs. About 300 adults will take the pill for 16 weeks. The goal is to see if their skin clears and itching improves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.